A standout in BMY's pipeline is Cobenfy, a drug for schizophrenia that has already outperformed other branded schizophrenia treatments. Its positive reception suggests strong commercial potential. In ...

A standout in BMY's pipeline is Cobenfy, a drug for schizophrenia that has already outperformed other branded schizophrenia treatments. Its positive reception suggests strong commercial potential.

In September 2024, the FDA approved the first new schizophrenia drug in more than 30 years, courtesy of Bristol Myers Squibb’s (BMS) Cobenfy (xanomeline and trospium chloride). The approval validated ...

The new drug Cobenfy, formerly known as KarXT ... as well as symptoms that can affect coping with daily life. “They may start to have difficulty keeping up with their activities of daily ...

The Food and Drug Administration approved the first new drug in over 30 years to treat schizophrenia in adults. The new drug Cobenfy, formerly known as KarXT, is manufactured by Bristol Myers ...

For instance, cobenfy is the first new schizophrenia drug approved in nearly three decades. Developed by Karuna Therapeutics and later acquired by Bristol Myers Squibb, it targets the cholinergic ...

The company is looking to compete with Bristol Myers Squibb’s Cobenfy, which received U.S. approval in September. Bristol and AbbVie’s drugs belong to a new class of treatments that aim to reduce ...

Cobenfy could be the first drug specifically approved for Alzheimer's-related psychosis, said Chief Commercialization Officer Adam Lenkowsky. Get local news you need to know to start your day ...

Bristol Myers Squibb believes Alzheimer's treatment is the largest potential market for its newly approved schizophrenia drug, Cobenfy ... company also expects to start phase three trials in ...